Journal of Clinical Oncology | Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF

Reply to H. Zetterberg et al.

Journal of Clinical Oncology

James L. Rubenstein, Lingjing Chen, Cigall Kadoch, Sushmita Roy, Chris Becker, Howard Schulman

Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy.

Journal of Clinical Oncology

J. L. Rubenstein, C. Kadoch, V. S. Wong, W. Hyun, C. Lowell

Suppressive signals in colorectal cancer: RasGRP1 a new marker for anti-EGFR therapy?.

Journal of Clinical Oncology

Jeroen Roose, Philippe Depeille, Robert S. Warren

Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma.

Journal of Clinical Oncology

James L. Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen, Mallory Kock, Wesley Cheung, Xiaomin Wang, Pamela N. Munster, Bertil Damato

Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.

Journal of Clinical Oncology

Lauren K. Meyer, Cristina Delgado-Martin, Ritu Roy, Benjamin J. Huang, Tiffaney Vincent, Adam Olshen, Brent L. Wood, Yu Liu, Jinghui Zhang, Charles Grenfell Mullighan, Terzah M. Horton, Mignon L. Loh, Meenakshi Devidas, Elizabeth A. Raetz, Robert J. Hayashi, Stuart Winter, Kimberly P. Dunsmore, Stephen Hunger, David T. Teachey, Michelle L. Hermiston

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.

Journal of Clinical Oncology

Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Lakshmi Nayak, John Paul Leonard, James L. Rubenstein

Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.

Journal of Clinical Oncology

Lauren K. Meyer, Ritu Roy, Benjamin J. Huang, Cristina Delgado-Martin, Tiffaney L. Vincent, Brent L. Wood, Yu Liu, Jinghui Zhang, Charles Grenfell Mullighan, Terzah M. Horton, Mignon L. Loh, Meenakshi Devidas, Elizabeth A. Raetz, Robert J. Hayashi, Stuart S. Winter, Kimberly P. Dunsmore, Stephen Hunger, David T. Teachey, Adam B. Olshen, Michelle L. Hermiston

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).

Journal of Clinical Oncology

Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Lakshmi Nayak, John Paul Leonard, James L. Rubenstein

Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis.

Journal of Clinical Oncology

J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman

Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis.

Journal of Clinical Oncology

J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman

Subscribe to Journal of Clinical Oncology